Welcome to CDC stacks | Post-Marketing Surveillance of Human Rabies Diploid Cell Vaccine (Imovax) in the Vaccine Adverse Event Reporting System (VAERS) in the United States, 1990‒2015 - 41548 | CDC Public Access
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Post-Marketing Surveillance of Human Rabies Diploid Cell Vaccine (Imovax) in the Vaccine Adverse Event Reporting System (VAERS) in the United States, 1990‒2015
Filetype[PDF-466.77 KB]


Details:
  • Personal Authors:
  • Keywords:
  • Pubmed ID:
    27410239
  • Pubmed Central ID:
    PMC4943633
  • Description:
    Background

    In 1980, human diploid cell vaccine (HDCV, Imovax Rabies, Sanofi Pasteur), was licensed for use in the United States.

    Objective

    To assess adverse events (AEs) after HDCV reported to the US Vaccine Adverse Event Reporting System (VAERS), a spontaneous reporting surveillance system.

    Methods

    We searched VAERS for US reports after HDCV among persons vaccinated from January 1, 1990–July 31, 2015. Medical records were requested for reports classified as serious (death, hospitalization, prolonged hospitalization, disability, life-threatening-illness), and those suggesting anaphylaxis and Guillain-Barré syndrome (GBS). Physicians reviewed available information and assigned a primary clinical category to each report using MedDRA system organ classes. Empirical Bayesian (EB) data mining was used to identify disproportional AE reporting after HDCV.

    Results

    VAERS received 1,611 reports after HDCV; 93 (5.8%) were serious. Among all reports, the three most common AEs included pyrexia (18.2%), headache (17.9%), and nausea (16.5%). Among serious reports, four deaths appeared to be unrelated to vaccination.

    Conclusions

    This 25-year review of VAERS did not identify new or unexpected AEs after HDCV. The vast majority of AEs were non-serious. Injection site reactions, hypersensitivity reactions, and non-specific constitutional symptoms were most frequently reported, similar to findings in pre-licensure studies.

  • Document Type:
    Journal Article
  • Collection(s):
    CDC Public Access
No Related Documents.
You May Also Like:
  1. Human rabies prevention -- United States, 2008; recommendations of the Advisory Committee on Immunization Practices
    Personal Author:
    Dhankhar, Praveen; Fishbein, Daniel; Guerra, Marta; Hanlon, Cathleen A.; Hull, Harry F.; Jenkins, Suzanne R.; Lumlertdacha, Boonlert; Manning, Susan E.; Meltzer, Martin I.; Rupprecht, Charles Edward; Sun, Benjamin; Vaidya, Sagar A.;
    Corporate Author:
    United States, Advisory Committee on Immunization Practices.; National Center for Zoonotic, Vector-Borne and Enteric Diseases (U.S.);
    Published:
    May 23, 2008
    Series:
    MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports ; v. 57, no. RR-3
    Description:
    "These recommendations of the Advisory Committee on Immunization Practices (ACIP) update the previous recommendations on human rabies prevention (CDC. Human rabies prevention---United States, 1999: recommendations of the Advisory Committee on Immuniz...
    File Type:
    Filetype[PDF - 547.77 KB]
  2. Human rabies prevention--United States, 2008 : recommendations of the Advisory Committee on Immunization Practices
    Personal Author:
    Briggs, Deborah.; Brown, Catherine M.; Cieslak, Paul R.; Franka, Richard.; Katz, Samuel L., 1927-; Kerr, Harry D.; Lett, Susan M.; Levis, Robin.; Meltzer, Martin I.; Rupprecht, Charles Edward.;
    Corporate Author:
    Centers for Disease Control and Prevention (U.S.). Office of Workforce and Career Development. Preventive Medicine Residency.; National Center for Immunization and Respiratory Diseases (U.S.). Immunization Services Division.; National Center for Preparedness, Detection, and Control of Infectious Diseases (U.S.). Division of Emerging Infections and Surveillance Services.; National Center for Zoonotic, Vector-Borne and Enteric Diseases (U.S.). Division of Viral and Rickettsial Diseases.; United States. Advisory Committee on Immunization Practices.;
    Published:
    May 23, 2008
    Source:
    MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control. 2008; 57(RR-3):1-28.
    Description:
    These recommendations of the Advisory Committee on Immunization Practices (ACIP) update the previous recommendations on human rabies prevention (CDC. Human rabies prevention--United States, 1999: recommendations of the Advisory Committee on Immunizat...
    Status:
    current
    File Type:
    Filetype[PDF - 547.77 KB]
  3. Compendium of animal rabies prevention and control, 2008: National Association of State Public Health Veterinarians, Inc. (NASPHV).
    Corporate Author:
    National Association of State Public Health Veterinarians, Inc.
    Source:
    MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control. 2008; 57(RR-2):1-9.
    Description:
    Rabies is a fatal viral zoonosis and a serious public health problem. The disease is an acute, progressive encephalitis caused by a lyssavirus. Although the United States has been declared free of canine rabies virus variant transmission, multiple vi...
    Status:
    current
    File Type:
    Filetype[PDF - 547.77 KB]
  4. Human rabies prevention -- United States, 1999 : recommendations of the Advisory Committee on Immunization Practices (ACIP)
    Personal Author:
    Arguin, Paul M.
    Corporate Author:
    National Center for Infectious Diseases (U.S.). Division of Viral and Rickettsial Diseases.
    Published:
    January 8, 1999
    Source:
    MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control. 1999; 48(RR-1):1-21.
    Description:
    These revised recommendations of the Advisory Committee on Immunization Practices update the previous recommendations on rabies prevention (MMWR 1991;40[No.RR-3]:1-14) to reflect the current status of rabies and antirabies biologics in the United Sta...
    Status:
    superseded
    File Type:
    Filetype[PDF - 359.26 KB]
  5. Adverse events following vaccination with an inactivated, Vero cell culture-derived Japanese encephalitis vaccine in the United States, 2009–2012
    Personal Author:
    Rabe, Ingrid B.; Miller, Elaine R.; Fischer, Marc; Hills, Susan L.;
    Published:
    Dec 09 2014
    Source:
    Vaccine. 33(5):708-712.
    Description:
    Background : In March 2009, the U.S. Food and Drug Administration licensed an inactivated, Vero cell culture-derived Japanese encephalitis vaccine (JE-VC [Ixiaro]) for use in adults. The vaccine was licensed based on clinical trial safety data in 355...
    File Type:
    Filetype[PDF - 84.50 KB]